Roche, already partnered with Poseida Therapeutics in the development of off-the-shelf cell therapies for blood cancers, is broadening its ambitions with the modality through a deal to acquire the ...

Roche Holding AG's acquisition of Poseida for $1.5bn is a smart move by Big Pharma as allogeneic cell therapies are becoming increasingly de-risked. Despite recent challenges, Roche's diverse ...

Roche has struck a $1.5 billion deal to buy Poseida Therapeutics. The takeover will establish off-the-shelf cell therapies, which Roche has said can democratize CAR-Ts, as a new core capability at the ...

We're maintaining our CHF 379/$55 fair value estimates for Roche's nonvoting shares following news of an oncology trial failure as well as a cell therapy acquisition. Roche announced that the ...